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Recent studies demonstrate that iron chelators possess marked potential as 
anticancer agents and also as substances protecting sensitive tissues against oxidative 
stress. This thesis is dealing mainly with design and synthesis of new antiproliferative 
iron chelators based on the structure of salicylaldehyde isonicotinoyl hydrazone (SIH) 
and with a characterization of their pharmacological and toxicological properties. 
Antiproliferative effects of these substances were studied on human breast 
adenocarcinoma cell line and human leukemic cell line and the non-specific toxicity on 
neonatal rat cardiac tissue-derived cells. During these studies some novel structure-
activity relationships have been found. Furthermore, the suitability of simultaneous 
administration of iron chelators with antineoplastic agents used in breast cancer 
treatment was studied. In this project the anthracycline antibiotic, doxorubicin, and, in 
particular, the estrogen receptor antagonist, tamoxifen, were identified as the most 
suitable agents for potential treatment combined with iron chelation therapy. The 
characterization of biological activities and structure-activity relationships of 
thiosemicarbazone chelators was also studied. One of the most potent 
thiosemicarbazone chelators identified in last years was characterized in terms of its 
biological activities. The chelation and antiproliferative activities of its recently 
identified phase I metabolites were also characterized and compared to the parent 
substance. The metabolic products were a few orders of magnitude less 
antiproliferatively active than its parent substance and non-toxic. Finally, we studied the 
ability of iron chelators to protect cardiac cells against oxidative stress-induced injury 
and anthracycline toxicity. Collectively, our results are important for further 
development of this novel group of potential anticancer agents and substances able to 
protect cardiac tissue. 
 
